首页> 外文期刊>Therapeutic delivery >Development and in vitro evaluation of solid dispersions as strategy to improve albendazole biopharmaceutical behavior
【24h】

Development and in vitro evaluation of solid dispersions as strategy to improve albendazole biopharmaceutical behavior

机译:固体分散体的开发和体外评价为改善阿贝扎唑生物手术行为的策略

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: Solid dispersions using Poloxamer 407 as carrier were developed to improve albendazole (ABZ) solubility and dissolution profiles. Methods: ABZ/poloxamer solid dispersions were prepared, and dissolution profiles were mathematically modeled and compared with physical mixtures, pharmaceutical ABZ and a commercial formulation. Results: Poloxamer 407 increased exponentially ABZ solubility, in about 400% when 95% w/w of polymer compared with its absence. Solid dispersions initial dissolution rate was three to 20-fold higher than physical mixtures, the drug and the commercial formulation. All the solid dispersions required less than 2.2 min to reach an 80% of ABZ dissolution, while the commercial formulation needed around 40 min. Conclusion: Solid dispersions improved ABZ solubility and dissolution rate, which could result in a faster absorption and an increased bioavailability.
机译:目的:使用泊洛沙姆407作为载体的固体分散体,以改善阿贝扎唑(ABZ)溶解度和溶解曲线。 方法:制备ABZ /泊洛沙姆固体分散体,并与物理混合物,药物ABZ和商业配方进行数学建模并将溶解谱进行。 结果:泊洛沙姆407增加了指数增长的ABZ溶解度,当聚合物的95%w / w相比,约400%。 固体分散体初始溶出速率高于物理混合物,药物和商业制剂的3至20倍。 所有固体分散体需要小于2.2分钟,达到ABZ溶解的80%,而商业制剂需要约40分钟。 结论:固体分散体改善了ABZ溶解度和溶出速率,这可能导致更快的吸收和增加的生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号